Intimation of classification of Unit-1 of Eugia Pharma Specialities Limited, a wholly owned subsidiary of the Company.
AUROPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
US FDA inspected Unit-I of Eugia Pharma Specialities Ltd, a wholly owned subsidiary of Aurobindo Pharma, from February 16-27, 2026. The inspection concluded with 4 observations. FDA has now classified the inspection as 'Official Action Indicated' (OAI), which is a negative regulatory classification indicating potential enforcement action. The company states there is no impact on its financials or operations due to this action. The facility is a formulation manufacturing unit located in Shameerpet, Telangana.
OAI classification is a serious regulatory concern as it may lead to warning letters or import alerts, potentially affecting exports to the US market. While the company claims no current financial impact, investors should monitor for further FDA communications.